ENCHROMA
15.7.2024 18:09:34 CEST | Business Wire | Press release
Opera di Religione della Diocesi di Ravenna, EnChroma, manufacturers of lenses for color blind users, Francesca Carlone, sustainable designer and founder of the project, Fondazione Paolina Brugnatelli and ITRIA announce today an initiative to enhance the experience of color blind visitors. Starting July 19, 2024, visitors with this vision condition will be able to borrow special glasses during their visit to live for the first time the experience of seeing light and bright color mosaics. The project, called ColoRaMi - color mosaics, will be introduced on July 19 at Basilica di Sant’Apollinare Nuovo as part of the Ravenna Mosaici FOR ALL program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240714597763/en/
Basilica di San Vitale: Agnus Dei. Normal colour vision and colour blind view (Graphic: Business Wire)
In Italy, approximately 2.5 million people are color blind, a vision condition affecting a higher number of men (8%) vs. women (0.5%) and approximately 350 million people worldwide. Whereas people with normal color vision can see over one million shades of color, people with color vision deficit only see 10% of tones and shades. As a result, colors can appear dull or even indistinguishable. EnChroma lenses allow people with deuteranomaly and protanomaly to perceive a much wider range of colors.
Artistic and cultural heritage is enhanced also by improving its accessibility, safety, and inclusiveness. Thanks to ColoRaMi, Ravenna's Mosaics will be the world's first mosaics to be made accessible to color blind people. Starting Friday, July 19, EnChroma glasses will be distributed free of charge at the following locations: Basilica of Sant’Apollinare Nuovo, Mausoleum of Galla Placidia, Basilica of San Vitale, Neonian Baptistry, Archiepiscopal Museum, and Sant’Andrea Chapel, thus enabling visitors to see for the first time the mosaics in all their chromatic complexity.
The opening event on July 19, at 3:00 p.m. will host a “live reveal” event, in which a number of color blind participants will share the daily challenges of color blindness and the difference made by EnChroma lenses in their viewing experience of the multicolor nuances of the mosaics.
EVENT INFO:
When: Friday, July 19 at 3:00 p.m.
Where: Basilica of Sant’Apollinare Nuovo
What's a Live Reveal:
A "Live Reveal" is an opportunity for volunteers to test EnChroma glasses for the first time and share their experience. At the end of the day, the volunteers may keep their custom-made glasses.
About EnChroma glasses:
EnChroma glasses are the product of two NIH research grants and of clinical studies conducted at UC Berkeley and UC Davis, USA. In 2016, EnChroma glasses were awarded the Tibbetts Award by the U.S. Small Business Administration for their innovative technology-driven impact on individual experience. EnChroma glasses use special optical filters that help people with color vision deficiency (protanomaly and deuteranomaly) experience a wider range of colors, perceiving them as more accurate, brighter, and sharper. Please note: EnChroma glasses do not treat color blindness and work for 9 out of 10 color blind wearers.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240714597763/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Technology Innovation Institute Completes Asteroid-Landing Probe for Landmark Emirates Mission to the Asteroid Belt5.10.2026 09:42:00 CEST | Press release
In a first-of-its-kind mission, TII’s probe aboard the MBR Explorer will journey past six asteroids in the main belt before landing on 269 Justitia, making it only the seventh asteroid in history to be reached on its surface by a probeDesigned, built and tested in Abu Dhabi, TII’s probe is the mission’s only deployable payload, operating fully autonomously around and on JustitiaThought to have formed in the distant Kuiper Belt in the outer Solar System, 269 Justitia may preserve clues to how water and organic material were distributed during the formation of the planetsWatch the EMA hero film here The Technology Innovation Institute (TII) has revealed the UAE-built probe it has developed for the Emirates Mission to the Asteroid Belt (EMA). The probe will soon travel to Colorado, USA, for final integration with the MBR Explorer spacecraft ahead of its planned 2028 launch. In a historic first, TII’s probe will image two planets and seven asteroids — flying past six asteroids in the main
JEOL: Sales launch of HAXIS: The New Low-angle Ion Milling Scanning Electron Microscope5.10.2026 09:30:00 CEST | Press release
JEOL Ltd. (President & CEO Izumi Oi) announces the development of its new low‑angle ion‑milling scanning electron microscope, HAXIS, and will commence sales on October 5, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260928207899/en/ HAXIS Low-angle Ion Milling Scanning Electron Microscope HAXIS Low-angle Ion Milling Scanning Electron Microscope Background of development As advanced semiconductor device structures continue to shrink and grow more complex, it has become difficult to contact and measure microscale circuits using nano-manipulators. In addition, contact caused by probing may affect the analysis target, necessitating new failure analysis methods. JEOL has conducted long-term research on the passive voltage contrast (PVC) detection technology and established a method for stable, highly reproducible PVC observation technology through the advancement of detectors and sample preparation techniques. HAXIS is JE
Slate Asset Management and OneIM Agree to Acquire Portfolio of Grocery-Anchored Essential Real Estate in the Greater Oslo Region Valued at Approximately €250 Million5.10.2026 08:30:00 CEST | Press release
Slate Asset Management ("Slate"), a global investor and manager focused on essential real estate and infrastructure assets, and One Investment Management (“OneIM”), a global alternative investment manager, today announced they have agreed to acquire a portfolio of eight grocery-anchored retail parks in Norway from Tellus Eiendom AS. The portfolio is located in the Greater Oslo region and is anchored by Norway's leading grocery operators and discount retailers. “We are pleased to be expanding our European Essential real estate platform with this significant acquisition,” said Brady Welch, Co-Founding Partner of Slate Asset Management. “These eight retail parks sit in dominant locations along major transport corridors around Oslo. The portfolio is anchored by Norway's strongest grocery operators and benefits from CPI-linked lease structures, designed to provide durable, inflation-protected cash flows. We look forward to applying our active management to unlock the portfolio’s full potent
Bial Showcases Parkinson’s Research at MDS 20265.10.2026 08:00:00 CEST | Press release
New data provide insights into the experiences and perceptions of people living with Parkinson’s and treatment outcomes Three posters and one oral presentation focus on the discontinued investigational compound BIA 28-6156 [INTENDED FOR MEDICAL AND TRADE MEDIA ONLY] Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, is presenting 16 scientific posters at the International Congress of Parkinson’s Disease and Movement Disorders (MDS 2026), taking place in Seoul, Korea, from 4 to 8 October. Reflecting Bial’s commitment to listening to and learning directly from people living with Parkinson’s, two presentations cover research initiatives focused on understanding their experiences, perspectives, and priorities. The first is the Patient Endpoint Preference Project (PEPP), an ongoing multinational observational study that seeks to identify and prioritise the symptoms and outcomes that matter most to people living with Parkinson’s. The second is th
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 16:50:00 CEST | Press release
Survival estimate remained at 48% between years two and three, extending evidence of durable benefitResults observed in heavily pretreated, difficult-to-treat population that received a median of four prior lines of therapy; nearly three-quarters of patients had platinum-resistant or refractory cancer Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
